Deadline fast approaching for Canadians to file claim in class-action drug suit
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
MONTREAL – The deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.
Canadians have until Aug. 27 to file a claim for their share of a $4.75 million settlement over the antipsychotic medication used to treat schizophrenia and depression.
Quebec Superior Court approved the settlement in November, one year after authorizing the national class action against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.
The class action covers Canadians who were prescribed the drug since February 2017 and later developed compulsive behaviours or impulse-control disorders such as gambling, shopping or binge-eating.
Lawyers representing affected patients and families have said the deal is a compromise with no admission of liability.
Applicants could receive anywhere from roughly $6,500 for mild cases to more than $102,000 in more severe cases.
This report by The Canadian Press was first published July 27, 2026.